SF1126 Terminated Phase 2 Trials for Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02644122SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes